Director at Cognition Therapeutics (CGTX) receives 25,000 RSUs and holds 73,500 shares

Rhea-AI Filing Summary

Monia Brett P reported acquisition or exercise transactions in this Form 4 filing.

Cognition Therapeutics Inc. director Brett P. Monia received an award of 25,000 restricted stock units (RSUs). These RSUs represent a right to receive an equal number of common shares at no purchase price per share.

The RSUs vest in full on the earlier of June 17, 2027 or the date of the company’s next annual meeting of stockholders, as long as Monia continues to serve as a director through that date. Following this grant, Monia directly holds 73,500 shares of Cognition Therapeutics common stock.

Insights

Equity compensation analyst

Routine director equity grant in RSUs with time-based vesting.

Director Brett P. Monia was granted 25,000 RSUs, a standard form of non-cash compensation that aligns director incentives with shareholders by tying value to future stock performance rather than salary.

The RSUs vest in full on the earlier of June 17, 2027 or the next annual stockholder meeting, conditioned on continued board service. This is a typical time-based vesting schedule for outside directors and does not, by itself, signal a change in the company’s outlook.

After the grant, Monia holds 73,500 common shares directly. With no derivative positions reported in this filing and no open-market buying or selling, the filing mainly updates the equity compensation profile rather than indicating a directional trading view.

Insider Trade Summary

Net Buyer: 25,000 shares

Net Buy 1 txn

Insider Monia Brett P

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	25,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 73,500 shares (Direct)

Footnotes (1)

1. F1. Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 17, 2027 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.

Key Figures

RSU grant size: 25,000 RSUs Grant price per share: $0.0000 per share Shares held after grant: 73,500 shares +2 more

5 metrics

RSU grant size 25,000 RSUs Award of restricted stock units to director Brett P. Monia

Grant price per share $0.0000 per share Stated price for RSU award

Shares held after grant 73,500 shares Total Cognition Therapeutics common shares held directly after transaction

Vesting date June 17, 2027 Latest possible full vesting date for RSUs, subject to earlier annual meeting

Vesting condition Continuous director service RSUs vest only if service continues through vesting date

Key Terms

restricted stock unit ("RSU"), contingent right, annual meeting of stockholders, continuous service

4 terms

restricted stock unit ("RSU") financial

"Each share is represented by a restricted stock unit ("RSU")."

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock"

annual meeting of stockholders financial

"on the date of the Issuer's next annual meeting of stockholders"

continuous service financial

"subject to the Reporting Person's continuous service as a director as of the applicable vesting date"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/22/2026 - 05:17 PM Accepted by SEC EDGAR 06/22/2026 - 05:16 PM Learn about SEC filing dates

FAQ

What did Cognition Therapeutics (CGTX) disclose about director Brett Monia in this Form 4?

Cognition Therapeutics reported that director Brett P. Monia received 25,000 restricted stock units. Each RSU entitles him to one share of common stock upon vesting, updating his equity-based compensation and total reported holdings in CGTX shares.

How many RSUs did the Cognition Therapeutics (CGTX) director receive and at what price?

Brett P. Monia received 25,000 restricted stock units of Cognition Therapeutics common stock. The grant carries a stated price of $0.0000 per share, reflecting that RSUs are compensation awards rather than open-market purchases of CGTX shares.

When do Brett Monia’s RSUs in Cognition Therapeutics (CGTX) vest?

The 25,000 RSUs vest in full on the earlier of June 17, 2027 or Cognition Therapeutics’ next annual meeting of stockholders. Vesting is contingent on Monia’s continuous service as a director through the applicable vesting date specified in the grant.

How many Cognition Therapeutics (CGTX) shares does Brett Monia hold after this RSU grant?

Following the reported RSU award, Brett P. Monia directly holds 73,500 shares of Cognition Therapeutics common stock. This total reflects his updated beneficial ownership position after the 25,000 restricted stock units were granted as equity compensation.

Are the RSUs granted to the Cognition Therapeutics (CGTX) director subject to any service conditions?

Yes. The RSUs vest only if Brett P. Monia maintains continuous service as a director through either June 17, 2027 or the date of Cognition Therapeutics’ next annual stockholder meeting, whichever occurs first under the award’s terms.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Monia Brett P

(Last) (First) (Middle)

C/O COGNITION THERAPEUTICS INC

2500 WESTCHESTER AVE.

(Street)

PURCHASE NEW YORK 10577

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
COGNITION THERAPEUTICS INC [ CGTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2026		A		25,000(1)	A	$0.00	73,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 17, 2027 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.

	/s/ John Brendan Doyle, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)